Research programme: glutathione-independent formaldehyde dehydrogenase inhibitors - SAJE PharmaAlternative Names: SPL 227; SPL 875; SPL 891
Latest Information Update: 12 Mar 2016
At a glance
- Originator SAJE Pharma
- Mechanism of Action Glutathione-independent formaldehyde dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Unspecified
Most Recent Events
- 11 Mar 2016 Preclinical trials in Inflammation in USA (unspecified route) before March 2016
- 11 Mar 2016 Preclinical trials in Undefined indication in USA (unspecified route) before March 2016